Serum levels of IL-6 correlated with the tumor stage of the RCC and was therefore considered a prediction factor of disease recurrence, progression, and OS and disease-specific (DS) survival [222,223,224,225,226,227,228]. This evidence concerns the gene IL6 and renal cell carcinoma.